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Background: Central lymph node metastasis of papillary thyroid microcarcinoma (PTMC) is common; however,
prophylactic central lymph node dissection (CLND) is still controversial because of the possible increased morbidity.
The purpose of this study is to determine the clinical outcome of patients with cN0 PTMC by central neck
dissection.
Methods: A retrospective cohort study was conducted on patients with PTMC without preoperative evidence of
lymph node disease (cN0), and the outcomes were compared between patients undergoing total thyroidectomy
(TT) alone (group A) and patients undergoing TT with CLND (group B).
Results: In this study, 242 patients with cN0 PTMC were included. Group A had 108 patients and group B had 134
patients. During a follow-up of over 60 months, the long-term postoperative complications were equivalent between
the two groups. In group B, the presence of involved central neck lymph nodes upstaged 16% of patients to stage III
disease, which necessitated additional postoperative radioactive iodine treatment. More patients had recurrences in
group A. The rate of reoperation in the central compartment was higher in group A than in group B (8.3% vs
2.2%, P < 0.01).
Conclusions: Prophylactic CLND does not increase long-term postoperative complications and reduces the risk
of recurrence in the central compartment.
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Despite the majority of papillary thyroid microcarcinoma
(PTMC) patients having benign clinical courses, metas-
tases to the lymph nodes are common. A report from
Mayo Clinic showed that one third of 900 PTMC pa-
tients had metastases at the time of diagnosis [1]. The
central neck compartment is the most common site of
metastases. Consequently, some surgeons recommend
routine prophylactic removal of the central neck lymph
nodes at the time of the initial operation [2,3]. However,
this was countered with some studies showing no benefit
[4,5]. The purpose of this study is to evaluate the influ-
ence of prophylactic central lymph node dissection* Correspondence: Liyangzhang25@hotmail.com
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patients with PTMC.Methods
This retrospective cohort study was performed of a sin-
gle institutional database of patients with histologically
proven PTMC (<1 cm) at Peking Union Medical College
Hospital from January 2008 to December 2009. Patients
who underwent total thyroidectomy (TT) alone were
designated as group A, whereas those who underwent
TT with prophylactic CLND were designated as group
B. Some surgeons in our institution performed routine
CLND, and these surgeons contributed patients to group
B. Those who did not perform CLND routinely contrib-
uted patients to group A. Patients with bilateral PTMC
underwent bilateral prophylactic CLND, while patients
with unilateral PTMC underwent ipsilateral CLND.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Median age 45 48 NS
Gender
Male 27 26 NS
Female 81 108 NS
Pathology
Median tumor size (cm) 0.5 0.7 NS
Extrathyroid extension 2 4 NS
Median nodes removed 0 6 <0.01
Median positive nodes 0 1 <0.01
Median MACIS score 3.8 4.1 NS
Median follow-up (months) 66 61 NS
NS, not significant.






Wound infection 0 0 NS
Hemorrhage 0 1 NS
Temporary hypocalcemia 10 (9%) 40 (30%) <0.01
Permanent hypoparathyroidism 0 2 NS
Temporary RLN injury 1 (0.9%) 2 (1.5%) NS
Permanent RLN injury 1 (0.9%) 1 (0.7%) NS
Mean parathyroids autotransplanted 0.1 0.65 <0.01
NS, not significant.
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nodes [6]. Patients with common papillary thyroid carcin-
oma (PTC) of >1 cm, evident preoperative abnormal
lymph nodes, distant metastasis, or previous operation for
PTC were excluded. Patients who underwent other opera-
tions such as lobectomy or subtotal thyroidectomy were
also excluded in order to keep homogeneity in the man-
agement of patients and to avoid interference on cancer
recurrence. Of the 709 patients treated surgically for PTC
from January 2008 to December 2009, 242 patients satisfied
the inclusion criteria. Of these, 108 patients underwent TT
alone and 134 patients underwent TT and CLND. Consent
statements were required from all patients.
We routinely removed badly blood-supported parathy-
roid during operation and cut it into 1-mm pieces to im-
plant in the sternocleidomastoid muscle. Patients were
monitored postoperatively with serum calcium determin-
ation. Temporary hypocalcemia was defined as serum
calcium <8 mg/dl anytime during the initial 6-month
follow-up. Permanent hypoparathyroidism was defined
as a need for continued calcium beyond 6 months after
surgery with persistent serum calcium <8 mg/dl. Transi-
ent recurrent laryngeal nerve (RLN) palsy was confirmed
by fiber optic laryngoscopy between 0 and 6 months after
operation, and permanent RLN palsy was confirmed by
fiber optic laryngoscopy beyond 6 months after operation.
Recurrence was defined as local or regional disease requir-
ing reoperation or other repeat treatment, as detected by
serial cervical ultrasonographies or radioactive thyroid
scan [6].
Patients underwent radioactive iodine ablative therapy
with iodine131 (I131) 3 to 4 weeks after operation. The in-
dications for I131 ablation were determined by the nu-
clear medicine specialists based on the American Joint
Committee on Cancer (AJCC) stage of disease [7]. All
patients entered a scheduled clinical follow-up program
on an average duration of over 60 months. Follow-up of
patients involved annual examination of neck ultrason-
ography, I131 scintigraphy, computed tomography, and
so on.
Statistical analysis was performed using SPSS13.0 software.
Data were compared for statistical analysis using the
chi-square test to evaluate differences between qualita-
tive variables and using Student’s t test to compare
quantitative variables. P < 0.05 was considered significant.
Results
Patient characteristics are summarized and operative re-
sults were analyzed between group A and group B based
on operative and surgical pathology reports in Table 1.
There were no significant differences in the age, gender
distribution, and tumor pathologic characteristics. In
group B, ipsilateral CLND was performed in 112 (84%)
patients and 31 (16%) had bilateral CLND. The numberof patients found to have involved central neck lymph
nodes on final pathology was 51 of 134 (38%) in group
B. The median number of lymph nodes excised was 0 in
group A and 6 in group B (P < 0.01). The median num-
ber of positive lymph nodes was 0 in group A and 1 in
group B (P < 0.01). A total of 22 (16%) patients over
45 years old were upstaged from stage I to stage III dis-
ease because of positive lymph node status according to
the AJCC staging system for differential thyroid cancer.
The incidence of operative complications is summa-
rized in Table 2. The incidence of postoperative infection
and hematoma was similar between the groups. There
were a significantly greater number of parathyroid auto-
transplantations due to devascularization and a higher
rate of temporary postoperative hypocalcemia in group
B. Permanent hypoparathyroidism was equivalent be-
tween the groups. There was no difference in the inci-
dence of temporary and permanent RLN injury between
group A and group B. We did not list the complications
of CLND in the reintervention because the number was
too small to make a statistical analysis and compare it
with that of the initial operation. There were 12 recur-
rences in both groups, and 8 of them had re-CLND, 2 of
Figure 1 Central compartment recurrence-free survival.
Table 3 Disease recurrence requiring reoperation




Reoperation 9 (8.3%) 3 (2.2%) <0.01
Central 7 (6.5%) 1 (0.7%) <0.01
Lateral 5 (4.6%) 3 (2.2%) NS
Central plus lateral 3 (2.8%) 1 (0.7%) <0.01
NS, not significant.
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hypocalcemia, which was much higher than that of the
initial operation.
During the final follow-up, no one died in this study.
A Kaplan-Meier survival analysis for central compart-
ment reoperation was undertaken. Group B, which had
prophylactic CLND, had a significantly lower failure rate
(P < 0.05) compared with group A, which did not have
CLND (shown in Figure 1). There was no recurrence in
the thyroid bed. All 12 recurrences occurred in regional
lymph nodes, 4 of whom had both central and lateral
section lymph node recurrences. Recurrent disease oc-
curred in 9 of 108 (8.3%) in group A and 3 of 134 (2.2%)
in group B (P < 0.01). In 8 central compartment lymph
node (levels VI and VII) recurrences, 7 (6.5%) was in
group A and 1 (0.7%) was in group B (P < 0.01). In 8 lat-
eral section lymph node (levels IV, III, and II) recur-
rences, 5 (4.6%) was in group A and 3 (2.2%) was in
group B (NS). Eight of 12 recurrences had re-CLND
(levels VI and VII), 4 of whom had both central (levels
VI and VII) and lateral (levels IV, III, and II) section re-
operation. The median time to reoperation in group B was
longer than that in group A (27 vs 18 months, P < 0.05).
The rate of reoperation in the central compartment was
significantly higher in group A than in group B (6.5% vs
0.7%, P < 0.01). Although the rate of reoperation in the lat-
eral section in group B (2.2%) was lower than that in group
A (4.6%), there was no statistical significance. Data sum-
marizing reoperation rates and regions of lymph nodes re-
moved at secondary surgery are shown in Table 3.Discussion
The incidence of PTMC has been increasing within the
recent 5 years with the extensive use of thyroid ultrason-
ography in routine physical examination [8]. Although it
has been accepted that patients with PTMC have a good
prognosis [9], cervical lymph node metastases are com-
mon, with an incidence between 30% and 60% [1,10].
Furthermore, more and more researches reported that
regional lymph node metastasis was associated with in-
creased local recurrence rates and reduced survival
[11,12]. Therefore, there is renewed interest in the op-
erative management of cervical lymph node metastases,
but controversies remain. Most surgeons agree that
grossly involved lymph nodes in the central neck of pa-
tients with PTMC should be managed by selective
neck dissection. The debate focuses on whether the
use of prophylactic CLND at the initial thyroid operation
benefits PTMC patients. This retrospective cohort study
examined the impact of routine CLND in addition to TT
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creased recurrence rate and a reduction in the need for re-
operation in the central compartment without increasing
long-term postoperative complications.
Prophylactic CLND is defined as the removal of all
level VI and VII nodes when there is no evidence of
lymph node metastasis on preoperative clinical examin-
ation, imaging studies, or intra-operative visual inspec-
tion [6]. It has been reported that most of central lymph
node metastases are too small to be detected by sonog-
raphy [13,14]. We observed that approximately 40% of
the patients who underwent central neck dissection had
lymph node involvement despite negative preoperative
physical examination and ultrasonography in our study.
The presence of lymph node metastases upgraded 16%
of the patients above 45 years old with PTMC from
stage I to stage III for central neck dissection, which
provided improved staging accuracy rather than for the
removal of subclinical disease. It is important to note
that accurate staging is not only helpful for predicting
the prognosis but also crucial for determining which pa-
tients would need radioiodine treatment because for
PTMC patients without lymph node metastases, radioio-
dine therapy is not necessary.
Another advantage of prophylactic central lymph node
dissection is that it provides a clear surgical field for cen-
tral compartment lymph node dissection in the initial
operation. In contrast, reoperation after the development
of recurrence is a much more difficult and technically
challenging procedure, associated with an increased
morbidity.
Higher rates of complications such as temporary hypo-
calcemia, permanent hypoparathyroidism, and RLN palsy
are often cited in arguments against prophylactic CLND
in the treatment of PTMC [15,16]. Temporary hypopara-
thyroidism has been reported to be between 20% and 50%
[17-19]. Our comparison of the two groups confirms pre-
vious reports of increased temporary hypocalcemia with
CLND, which was caused by transient parathyroid dys-
function due to devascularization and could be corrected
by calcium supplementation. The rate of permanent hypo-
parathyroidism had no difference between the two groups
because of our routine use of intra-operative parathyroid
auto-transplantation. The rates of temporary and perman-
ent RLN injury did not increase with prophylactic CLND.
Despite high rates of temporary hypocalcemia, the pa-
tients in our study did get benefits from CLND. The re-
moval of subclinical metastases improved the recurrence
rate and avoided reoperation in the central compart-
ment, which may be associated with increased risks. As
expected, the rate of disease recurrence in group B is
lower than that in group A (2.2% vs 8.3%, P < 0.01). Most
of these recurrences were in the first 3 years after the
initial operation. The median time of reoperation ingroup B was also longer than that in group A (27 vs
18 months, P < 0.05). There was also a reduction in the
need for further surgery in the central compartment in
patients who had prophylactic CLND in comparison
with those who did not have (6.5% vs 0.7%, P < 0.01).
Although the rate of reoperation in the lateral neck in
group B is also lower than that in group A, there is no
statistically significant difference. Shen et al. have shown
a similar trend toward decreased recurrence in patients
undergoing prophylactic CLND [20].
The limitations of this study include its nonrando-
mized, retrospective design, leaving the results vulnerable
to selection biases. The strengths are its large population
and long-time follow-up.
Conclusions
In conclusion, this study evaluates the impact of prophy-
lactic CLND in addition to TT in the management of
patients with PTMC and shows that prophylactic CLND
for cN0 PTMC can be performed at the time of the ini-
tial operation without apparent increase in long-term
morbidity. Prophylactic CLND should be considered be-
cause it not only allows for more accurate staging by the
determination of lymph node status but also results in
lower recurrence rates of PTMC and a reduction in the
need for reoperation.
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